



Safety Data Sheet

Version 02 Issuing Date: 2023-07-28

1. Identification of the Substance/Mixture and of the Company/Undertaking

1.1 Product identifiers

Product name: Povidone K30

Brand name: KoVidone® K30

CAS-No.: 9003-39-8

REACH Registration No.: A registration number is not available for this substance as polymers are exempted from REACH registration.

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses: Laboratory chemicals, Manufacture of substances.

1.3 Details of the supplier of the safety data sheet

Company: Boai NKY Medical Holdings Ltd.

Address: No. 1888 East Wenhua Road, Boai, Jiaozuo, Henan Province, China 454450.

Tel.: +86 391 8696320

Fax: +86 391 8692950

Email address: sales@boai-nky.com

1.4 Emergency telephone number

Emergency Phone #: +86 22 58316066

2. Hazards Identification

2.1 Classification of the substance or mixture

Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.

This substance is not classified as dangerous according to Directive 67/548/EEC.

2.2 Label elements

The product does not need to be labelled in accordance with EC directives or respective national laws.

2.3 Other hazards

The product does not contain any substances listed on ECHA Candidate List having endocrine disruptor properties or any substances identified as an endocrine disruptor defined in Regulations (EC) 2017/2100 or (EC) 2018/605.

3. Composition/Information on Ingredients

3.1 Substances

Synonyms: Polyvinylpyrrolidone, PVP.

Formula: (C₆H₉NO)_x

Chemical name	Registration No.	CAS No.	EC No.	Concentration(%)	Classification	Specific concentration limits; M-Factors; Acute Toxicity Estimates(ATE)
Polyvinylpyrrolidone	N/A	9003-39-8	N/A	>95.0	N/A	-
2-pyrrolidone	N/A	616-45-5	210-483-1	≤3.0	Serious eye damage/eye irritation	-



Safety Data Sheet

Version 02 Issuing Date: 2023-07-28

					Category 2A; Reproductive toxicity Category 1B; H319, H360	
--	--	--	--	--	--	--

4. First Aid Measures

4.1 Description of first aid measures

If inhaled

If breathed in, move person into fresh air. If not breathing, give artificial respiration.

In case of skin contact

Wash off with soap and plenty of water.

In case of eye contact

Flush eyes with water as a precaution.

If swallowed

Never give anything by mouth to an unconscious person. Rinse mouth with water.

4.2 Most important symptoms and effects, both acute and delayed

Unexcreted particles may be phagocytized by cells of the reticuloendothelial system and deposited in storage sites in the liver, spleen, lung, and bone marrow resulting in the storage disease thesaurosis. Severity and symptoms depend on storage site and nature of the particle. Pathological changes are not necessarily attributed to the thesaurosis, but in some cases an inflammation or granulomatoma have occurred.

4.3 Indication of any immediate medical attention and special treatment needed

No data available.

5. Firefighting Measures

5.1 Extinguishing media:

Suitable extinguishing media

Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2 Special hazards arising from the substance or mixture

Carbon oxides, nitrogen oxides (NOx).

5.3 Advice for firefighters

Wear self contained breathing apparatus for firefighting if necessary.

5.4 Further information

No data available.

6. Accidental Release Measures

6.1 Personal precautions protective equipment and emergency procedures

Avoid dust formation. Avoid breathing vapors, mist or gas.

6.2 Environmental precautions

Do not let product enter drains.

6.3 Methods and materials for containment and cleaning up

Sweep up and shovel. Keep in suitable, closed containers for disposal.

6.4 Reference to other sections

For disposal see section 13.

7. Handling and Storage



Safety Data Sheet

Version 02 Issuing Date: 2023-07-28

7.1 Precautions for safe handling

Provide appropriate exhaust ventilation at places where dust is formed.

7.2 Conditions for safe storage, including any incompatibilities

Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

7.3 Specific end uses

No data available.

8. Exposure Controls/Personal Protection

8.1 Control parameters

Components with workplace control parameters

8.2 Exposure controls

Appropriate engineering controls

General industrial hygiene practice.

Personal protective equipment

Eye/face protection

Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166 (EU).

Skin protection

Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands. The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the Standard EN374 derived from it.

Body protection

Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the specific workplace. The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

Respiratory protection

Respiratory protection is not required. Where protection from nuisance levels of dusts is desired, use Type N95 (US) or Type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (RU).

9. Physical and Chemical Properties

9.1 Information on basic physical and chemical properties

a) Physical State	Solid, Powder
b) Colour	White or off white
c) Odour	Faint specific odour
d) Melting point/freezing point	>130°C
e) Boiling point or initial boiling point and boiling range	>130°C (Decomposition)



Safety Data Sheet

Version 02 Issuing Date: 2023-07-28

f) Flammability	Not highly flammable
g) Lower and upper explosion limit	Not applicable
h) Flash point	Not applicable
i) Auto-ignition temperature	Not applicable
j) Decomposition temperature	>130°C
k) pH	3.0~7.0 (1g in 20 mL)
l) Kinematic viscosity	Not applicable
m) Solubility	Fully soluble
n) Partition coefficient n-octanol/water (log value)	Not determined
o) Vapor pressure	Not applicable
p) Density and/or relative density	350-550 kg/m ³ (DIN EN ISO 60)
q) Relative vapor density	Not applicable
r) Particle characteristics	Dv50: 80-90µm (by Malvern 3000)

9.2 Other information

9.2.1 Information with regard to physical hazard classes

Not applicable. The substance is not classified as physical hazard.

9.2.2 Other safety characteristics

No data available.

10. Stability and Reactivity

10.1 Reactivity

No data available

10.2 Chemical stability

No data available

10.3 Possibility of hazardous reactions

No data available

10.4 Conditions to avoid

No data available

10.5 Incompatible materials

Strong oxidizing agents

10.6 Hazardous decomposition products

Other decomposition products-no data available

11. Toxicological Information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Acute toxicity

LD50 Oral-rat- 100,000mg/kg

Remarks: Diarrhoea

Skin corrosion/irritation

Skin-rabbit-No skin irritation



Serious eye damage/eye irritation

Eyes-rabbit-No eye irritation

Respiratory or skin sensitization

Will not occur

Germ cell mutagenicity

No data available

Carcinogenicity

This product is or contains a component that is not classifiable as to its carcinogenicity based on its IARC, ACGIH, NTP, or EPA classification.

IARC: 3-Group 3: Not classifiable as to its carcinogenicity to humans (1-Ethenyl-2-pyrrolidinone homopolymer).

Reproductive toxicity

No data available

Specific target organ toxicity – single exposure

No data available

Specific target organ toxicity – repeated exposure

No data available

Aspiration hazard

No data available

Potential health effects

Inhalation	May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion	May be harmful if swallowed.
Skin	May be harmful if absorbed through skin. May cause skin irritation.
Eyes	May cause eye irritation.

Signs and symptoms of exposure

Unexcreted particles may be phagocytized by cells of the reticuloendothelial system and deposited in storage sites in the liver, spleen, lung, and bone marrow resulting in the storage disease thesaurosis. Severity and symptoms depend on storage site and nature of the particle. Pathological changes are not necessarily attributed to the thesaurosis, but in some cases an inflammation or granulomatoma have occurred.

11.2 Information on other hazards

The product does not contain any substances listed on ECHA Candidate List having endocrine disruptor properties or any substances identified as an endocrine disruptor defined in Regulations (EC) 2017/2100 or (EC) 2018/605.

12. Ecological Information

12.1 Toxicity

No data available

12.2 Persistence and degradability



No data available

12.3 Bioaccumulation potential

No data available

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

No data available

12.6 Endocrine disrupting properties

The product does not contain any substances listed on ECHA Candidate List having endocrine disruptor properties or any substances identified as an endocrine disruptor defined in Regulations (EC) 2017/2100 or (EC) 2018/605.

12.7 Other adverse effects

No data available.

13. Disposal Considerations

13.1 Waste treatment methods

Product

Offer surplus and non-recyclable solutions to a licensed disposal company.

Contaminated packaging

Dispose of as unused product.

14. Transport Information

14.1 UN number or ID number

ADR/RID: -- IMDG: -- IATA: --

14.2 UN proper shipping name

ADR/RID: Not dangerous goods

IMDG: Not dangerous goods

IATA: Not dangerous goods

14.3 Transport hazard class(es)

ADR/RID: -- IMDG: -- IATA: --

14.4 Packing group

ADR/RID: -- IMDG: -- IATA: --

14.5 Environmental hazards

ADR/RID: -- IMDG: Marine pollutant: no IATA: --

14.6 Special precautions for user

No data available.

14.7 Maritime transport in bulk according to IMO instruments

Not harmful goods.

15. Regulatory Information

This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006 and



Safety Data Sheet

Version 02 Issuing Date: 2023-07-28

Regulation (EU) 2020/878 .

15.1 Safety, health and environmental regulations/legislation specific for the substance of mixture

No data available

15.2 Chemical safety assessment

No chemical safety assessment has been carried out for this substance by the supplier.

16 Other Information

Further information

The above information is believed to be correct, but does not intend to be all-inclusive and shall be used only as a guide. This material safety data sheet is based on our current knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any assurances on product properties and does not constitute a contractual legal relationship.

Boai NKY Medical Holdings Ltd. and its Affiliates shall not be held liable for any damage resulting from the handling or from the contact with the above product.

*© Boai NKY Medical Holdings Ltd. License granted to make unlimited paper copies for internal use.
The changing of this document is forbidden except with the consent of Boai NKY Medical Holdings Ltd.*
